BioTech
-
FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted
Scientists at the Food and Drug Administration have two big questions about Eli Lilly’s experimental Alzheimer’s drug donanemab ahead of…
Read More » -
Zepbound, Covid-19 vaccine, Lykos’ MDMA
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…
Read More » -
Eli Lilly’s Zepbound improved liver scarring in mid-stage MASH study
Eli Lilly’s blockbuster diabetes and obesity drug improved living scarring in a mid-stage study of the liver disease MASH, adding…
Read More » -
Gilead, Biomarin, Lykos, AstraZeneca news
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…
Read More » -
ASCO Takeaways: Winners, snoozers, and the art of cancer care
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual…
Read More » -
BridgeBio Pharma, Annexon Biosciences, Delfi
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…
Read More » -
Novartis is flashing warning signs about its newly acquired myelofibrosis drug
CHICAGO — Something is off about the way Novartis is talking about pelabresib, its newly acquired and costly treatment for…
Read More » -
Illumina board agrees to spin off Grail, as divestment plans proceed
Illumina said Monday afternoon that its board of directors had approved a spin-off of its cancer test subsidiary Grail, signaling…
Read More » -
CAR-T, money talk, and the cancer treatment ‘sandwich’
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual…
Read More » -
AstraZeneca says CAR-T shrank solid tumors in early trial
CHICAGO — A next-generation CAR-T therapy was able to substantially shrink tumors in patients with liver cancer in early clinical…
Read More »